Table 2.

The comparison of general data before treatment

	L and Con groups (n=120)			M group (n=53)			S group (n=67)
	L group	Con group	p-value	M1 group	M2 group	p-value	S1 group	S2 group	p-value
	(n=60)	(n=60)		(n=29)	(n=24)		(n=32)	(n=35)
Age (years)	67.40±7.727	69.50±6.604	0.112	67.34±7.898	69.9±6.171	0.200	67.5±7.573	69.2±7.051	0.337
Gender (male/female)	37/23	29/31	0.144	17/12	11/13	0.358	20/12	18/17	0.365
BMI (kg/m2)	22.37±1.946	23.29±4.033	0.109	22.23±1.868	23.25±3.802	0.210	22.45±2.012	23.36±4.285	0.273
Primary disease (cases)			0.332			0.710			0.877
Lung cancer	14	16		9	4		8	8
UGC	26	30		11	13		15	16
LGC	18	12		6	7		7	11
Other cancers	2	2		3	0		2	0
Incision site (cases)			0.698			0.175			0.869
Chest incision	14	16		9	4		8	8
Abdominal incision	33	26		14	12		16	18
TI	13	18		6	8		8	9
Initial pathogen (cases)			0.860			0.407			0.833
PA	14	15		10	9		6	6
EC	7	11		4	4		3	8
KP	15	7		4	4		8	6
AB	12	9		1	4		9	5
SM	2	6		2	3		1	4
EC	9	10		6	0		4	6
Other	1a	2b		2	0		1	0

Notes:

^aProteus mirabilis;

^bAcinetobacter junii. The Con group (conventional treatment group) received traditional infusion of TZP and the L group (improved administration group) received it as prolonged infusion. Blood drug concentration was detected at different time points. Based on the SOFA cut-off value of 9, the patients were regrouped into M (mild) and S (severe) groups. M1: mild group with prolonged administration; M2: mild group with traditional administration; S1: severe group with prolonged administration; S2: severe group with traditional administration.

Abbreviations: AB, Acinetobacter baumannii; BMI, body mass index; EC, Enterobacter cloacae; EC, Escherichia coli; KP, Klebsiella pneumoniae; LGC, lower gastrointestinal cancer; PA, Pseudomonas aeruginosa; SM, Serratia marcescens; TI, thoracoabdominal incision; UGC, upper gastrointestinal cancer.